CD274 and breast cancer: In BC, IMpassion130 trial demonstrated that atezolizumab combined with nab-paclitaxel significantly improve progression-free survival (PFS) and overall survival (OS) in patients with metastatic TNBC and PD-L1-positive subgroup with acceptable safety profile (7).